1AI 10.0% 0.9¢ algorae pharmaceuticals limited

Ann: Results of LCT Parkinsons trial require further analysis, page-109

  1. 54 Posts.
    whytee, you mention responsiveness to l-dopa. during the cc it was mentioned that all the patients in the phase1 trial had been approved for DBS and 1 criteria for that is good l-dopa responsiveness. it was stated all patients in phase2 had been diagnosed at least 5 years ago, under 65 and were heading towards getting a DBS eventually which implies L-DOPA responsiveness, i'm sure they must have measured them ON and OFF in the UPDRS motor test to make sure the responded well to l-dopa. you take the test 10hrs after your last meds, then take your meds and re-test 90minutes later. i assume they tried to select patients that didn't have atypical parkinson's. if you go to a parkinson's support group you'll quickly see no 2 pd'ers are alike.
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
0.9¢
Change
-0.001(10.0%)
Mkt cap ! $15.18M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $750 83.33K

Buyers (Bids)

No. Vol. Price($)
5 206531 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 383746 1
View Market Depth
Last trade - 14.28pm 12/07/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.